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Introduction: We present a case of active Behc¸et's disease in pregnancy. The literature specific to Behc¸et's in pregnancy is sparse, dominated by retrospective analyses and involving small numbers. It has been suggsested that the condition improves in pregnancy in the majority of patients.1 The literature suggests exacerbations in pregnancy are dominated by increases in the intensity and severity of outbreaks of oral ulcers during pregnancy2. We present a case of Behc¸et's disease in pregnancy with a history of recurrent uveitis requiring anti-TNF therapy before pregnancy, and with a severe flare of erythema nodosum during pregnancy. There are several case reports of the use of infliximab in pregnancy3. While our patient was on infliximab pre-conceptually, we opted to use certolizumab pegol during pregnancy due to the lower risk for transplacental transfer. Case description: We present the case of a 37-year old female patient with Behc¸et's disease in pregnancy. Behc¸et's had first been diagnosed in 2003 in another centre. She had a history of uveitis, vitritis, erythema nodosum, oral and genital ulceration, pustular rash, and arthralgia. She was HLA-B51 positive. She gave no history of vascular involvement. Other medical history included reflex anoxic seizures since childhood and surgery for talipes with left ankle fixation in childhood. She was first seen in our centre in February 2014 when she was on Infliximab 6 weekly, Prednisolone 7.5mg/10mg, and 3 monthly Vitamin B12 injections. She had been on infliximab for 6 years. She had previously tried azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, and thalidomide. She had had a previous pregnancy 4 years earlier during which she had continued infliximab until the end of the second trimester, restarting infliximab 5 weeks post partum. Infliximab was restarted to treat erythema nodosum which was unresponsive to high dose prednisolone (40mg). She had attended a tertiary referral centre during her first pregnancy which was complicated by uveitis with some residual eye damage. Her disease was stable on infliximab and when she was first seen in our centre had twooral ulcers only.She describeddisease reactivation 4weeksafter each infliximab infusion which was controlled with colchicine, flixotide MDI and difflam mouthwash. In 2014 she had an episode of uveitis. In 2015 she had a flare of erythema nodosum which resolved with colchicine. She subsequently became intolerant of colchicine. In 2016 she had an episode of vitritis. She had bilateral cataracts. Prednisolone doses were adjusted to resolve flares. She was otherwise stable. In 2016 the patient wished to try for a second child and became pregnant at the end of 2016 with anexpecteddate of deliveryin May 2017.As shewas well, infliximab was stopped in the first trimester. The obstetric team started low dose aspirin. As she entered the second trimester she developed acneiform pustules on the upper thighs and buttocks for which her prednisolone was increased to 15mg tailing down. We began to consider options if thiswasthe beginning of aBehc¸et'sflare whichwould requiremore definitive therapy. We considered restarting infliximab or using tacrolimus. She first developed a few minor EN lesions. These gradually worsened, until at 25 weeks she had extensive erythema nodosum covering her lower limbs and including her right arm. She felt systemically unwell. ESR was 93, CRP 30. She was seen in the combined Rheumatology/Dermatology clinic and prednisolone increased to 30mg daily. We were concerned that in addition to the patients current systemic symptoms, progression of her flare could include recurrence of uveitis. Her case was discussed with Dr Situnayake at the Birmingham Behc¸et's Syndrome National Centre of Excellence who advised starting certolizumab pegol. As this was unlicensed an urgent Individual Patient Funding Request was submitted and certolizumabpegolstartedat29weeks1 daygestation, with rapidresolution of erythema nodosum, systemic symptoms associated with active inflammation, and rapid decline in ESR. We were able to tail down the prednisolone dose from 30mg to 7.5mg. At 32 weeks gestation we were contacted by the obstetric team who were concerned that there would be increased intra-partum infection risk while on anti-TNF particularly in the event of a perineal tear or caesarean section, and suggested stopping certolizumab pegol at 36 weeks. An induction date for 39 weeks was planned. We advised continuation until 37 weeks, particularly as the patient previously flared rapidly on cessation of treatment and we suggested that high dose steroids and/or poorly controlled disease would put her at higher risk of infection and peripartum complications than continued use of anti-TNF. The patient had a spontaneous vaginal delivery at 37 weeks 6 days, delivering a healthy baby girl. The patient had no ulceration prior to delivery but experienced a 2cm tear during delivery which ulcerated 4 days post partum. The only Behcet's symptoms at delivery were a few pustules on one leg. The last certolizumab pegol had been given 3 days prior to delivery, and was next given 17 days later when the tear had fully healed. The patient opted to breastfeed. The guidance in the current BSR guidelines4 advises 'Women should not be discouraged from breastfeeding on TNFis, but caution is recommended until further information is available'. Breastfeeding was complicated by recurrent mastitis resulting in a two day admission seven weeks post partum. The patient is currently trying to manage breast feeding cessation while simultaneously managing the risk forrecurrent mastitis. Discussion:We present this case to contribute to the experience of using anti-TNF in pregnancy in general, and certolizumab pegol in particular as pegylation and reduced transplacental transfer may indicate it is the preferred anti-TNF in pregnancy. We also wish to contribute to the limited literature concerning Behc¸et's disease in pregnancy. Our patient experienced marked exacerbation of disease following withdrawal of infliximab in the first trimester. By controlling her disease using certolizumab pegol, she had minimal disease activity at delivery, and was able to remain well on low dose prednisolone whereas she had previously required high doses with all attendant risks. Our patient opted to breast feed while continuing on certolizumab pegol. This is an area with little data. Her experience was complicated by mastitis. This may have been incidental,butriskandseveritymayhavebeenincreasedbycertolizumab pegol, and will require further research as larger numbers of patients breastfeed while receiving anti-TNF therapy. Key learning points: Behcet's disease can flare in pregnancy. Use of anti-TNF to control significant flares is steroid sparing. Certolizumab pegol may have aspecific role in pregnancy due to minimaltransplacental transfer. Advice regarding breastfeeding remains equivocal and more research is needed to give greater confidence to doctors and patients. In our patient, breastfeeding was complicated by significant mastitis. Further research is required to assess the contribution to risk made by the use of anti-TNF. Greater awareness of the risk of mastitis may allow focused advice for and monitoring of these patients in the post partum period whenthey are establishing breastfeeding.
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